Stockscreener 앱 받기
12.58
1.37%
0.17
Phathom Pharmaceuticals Inc 주식(PHAT)의 최신 뉴스
Institutional investors in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) see US$88m decrease in market cap last week, although long-term gains have benefitted them. - simplywall.st
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026 - GlobeNewswire
Phathom Pharmaceuticals sponsors Great GI Debates to showcase GERD treatment - Traders Union
(PHAT) Volatility Zones as Tactical Triggers - Stock Traders Daily
Stop Loss: Does Phathom Pharmaceuticals Inc have strong fundamentalsTrade Analysis Report & Weekly Watchlist of Top Performers - baoquankhu1.vn
Stock Market Recap: What is Phathom Pharmaceuticals Incs TAM Total Addressable MarketJuly 2025 Selloffs & Reliable Intraday Trade Alerts - baoquankhu1.vn
Momentum Shift: Can NTST maintain its current growth ratePortfolio Risk Report & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Aug Final Week: What is Phathom Pharmaceuticals Incs book value per share2025 Technical Overview & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Millennium Management LLC Reduces Stake in Phathom Pharmaceuticals Inc - GuruFocus
What are the risks of holding Phathom Pharmaceuticals Inc.2025 Dividend Review & Advanced Technical Analysis Signals - mfd.ru
Is Phathom Pharmaceuticals Inc. a cyclical or defensive stockPortfolio Performance Summary & Growth Focused Entry Reports - mfd.ru
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
AIGH Capital Management LLC Acquires Shares of 429,000 Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Aug Drivers: Is DENNs growth already priced inJuly 2025 Trade Ideas & Precise Buy Zone Tips - baoquankhu1.vn
H.C. Wainwright Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $26 - 富途资讯
Phathom Pharmaceuticals surges 50% following large insider purchase - MSN
Phathom Pharma plans public offering after reporting preliminary 2025 results - MSN
Investment Review: Is Alexanders Inc a momentum stockJuly 2025 Volume & Technical Pattern Based Signals - baoquankhu1.vn
Phathom Pharmaceuticals stock maintains Buy rating at Stifel on strong revenue outlook - Investing.com Canada
Breakeven On The Horizon For Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - 富途牛牛
Cantor Fitzgerald reiterates Overweight rating on Phathom stock at $29 By Investing.com - Investing.com Canada
Bond Watch: Whats Phathom Pharmaceuticals Incs historical return2025 Technical Patterns & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
(PHAT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Phathom Pharmaceuticals: VOQUEZNA hits 1 million U.S. prescriptions milestone - Traders Union
Latham & Watkins Advises Phathom Pharmaceuticals on US$130 Million Public Offering of Common Stock and Pre-Funded Warrants - Legal Desire Media and Insights
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 7.6%Here's What Happened - MarketBeat
Phathom surges 125% after FDA grants petition on Voquezna exclusivity - MSN
Should Phathom’s US$130 Million Equity Raise and Profitability Timeline Update Require Action From Phathom Pharmaceuticals (PHAT) Investors? - Yahoo Finance
Phathom: Why I’m Not Buying The Dip (Yet) (NASDAQ:PHAT) - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), InMode (INMD) and Bristol-Myers Squibb (BMY) - The Globe and Mail
Phantom slumps 12%; prices $130M stock at $16 per share - MSN
Institution Moves: Can Phathom Pharmaceuticals Inc. stock hit analyst price targets2025 Market Trends & Free Expert Verified Stock Movement Alerts - Улправда
Phathom Pharma Shows Sales Strength, Targets 2026 Profitability - Sahm
How Phathom Pharmaceuticals Inc. stock performs in stagflationJuly 2025 Update & Safe Investment Capital Preservation Plans - Улправда
Phathom Pharmaceuticals Announces $130 Million Public Offering - TipRanks
Form 424B5 Phathom Pharmaceuticals, - StreetInsider
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap DownTime to Sell? - MarketBeat
Phathom Pharmaceuticals shares fall 13.1% after co announces $130 mln equity raise - marketscreener.com
Can Phathom Pharmaceuticals Inc. stock hit analyst price targetsTrade Performance Summary & Technical Entry and Exit Tips - Улправда
What's Going On With Phathom Pharma Stock Thursday?Phathom Pharmaceuticals (NASDAQ:PHAT) - Benzinga
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Drop— AZZ, Northrop Grumman, Immuneering In Focus (UPDATED) - Benzinga
Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Phathom Pharmaceuticals (PHAT) Benefits from Joint Book Running Managers - GuruFocus
Revenues Tell The Story For Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) As Its Stock Soars 27% - simplywall.st
Phathom Pharmaceuticals tumbles on $130 mln equity raise - TradingView — Track All Markets
Phathom Pharmaceuticals prices $130 million public offering By Investing.com - Investing.com Nigeria
Phathom Pharmaceuticals announces public offering of common stock By Investing.com - Investing.com Nigeria
Phathom Pharmaceuticals (PHAT) Launches $130M Public Offering - GuruFocus
Phathom Pharmaceuticals (PHAT) Prices Public Offering, Stock Dips - GuruFocus
Phathom (PHAT) Stock Pre-Market (-12%): Prices $130M Stock Offering at Discount - Trefis
Phathom Pharmaceuticals prices $130 million public offering - Investing.com
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants - Yahoo Finance
Drug maker plans $130M stock sale to fund new gut disease research - Stock Titan
0.23%
1.25%
자본화:
|
볼륨(24시간):